MedTrace Logo

Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan

NCT00687193 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 318

Last updated 2013-03-25

Study results available
· View outcomes & findings →

Summary

To evaluate the dose-response relationship of 5 dose of CP-690,550, compared to placebo for the treatment of signs and symptoms in patients with active RA who failed an adequate trial of therapy with at least 1 DMARD in a 12-week therapy.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Placebo

Placebo BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

10mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

15mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

1mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

3mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

5mg BID, 3 blinded tablets administered BID for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00687193 on ClinicalTrials.gov